Recent advances in Parkinson’s disease therapy: use of monoamine oxidase inhibitors

References

• Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol.17(7), 1285–1297 (1968).
   PubMed Web of Science ®Google Scholar
• O’Carroll AM, Fowler CJ, Phillips JP, Tobbia I, Tipton KF. The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions. Naunyn. Schmiedebergs Arch. Pharmacol. 322(3), 198–202 (1983).
   PubMed Web of Science ®Google Scholar
• Squires RF. Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: a comparison of eight mammalian species. Adv. Biochem. Psychopharmacol. 5, 355–370 (1972).
   PubMedGoogle Scholar
• Collins GG, Sandler M, Williams ED, Youdim MB. Multiple forms of human brain mitochondrial monoamine oxidase. Nature 225(5235), 817–820 (1970).
   PubMedGoogle Scholar
• Riederer P, Youdim MB. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J. Neurochem. 46(5), 1359–1365 (1986).
   PubMed Web of Science ®Google Scholar
• Green AR, Mitchell BD, Tordoff AF, Youdim MB. Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br. J. Pharmacol. 60(3), 343–349 (1977).
   PubMed Web of Science ®Google Scholar
• Ruggieri S, Fabbrini G, Bramante L et al. An open study with reversible MAO-A inhibitors in complicated Parkinson’s disease. Adv. Neurol. 69, 595–598 (1996).
   PubMedGoogle Scholar
• Sieradzan K, Channon S, Ramponi C, Stern GM, Lees AJ, Youdim MB. The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson’s disease. J. Clin. Psychopharmacol. 15(4 Suppl. 2), S51–S59 (1995).
   PubMed Web of Science ®Google Scholar
• Sternic N, Kacar A, Filipovic S, Svetel M, Kostic VS. The therapeutic effect of moclobemide, a reversible selective monoamine oxidase A inhibitor, in Parkinson’s disease. Clin. Neuropharmacol. 21(2), 93–96 (1998).
   PubMed Web of Science ®Google Scholar
• Youdim MB, Riederer PF. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson’s disease. Neurology 63(7 Suppl. 2), S32–S35 (2004).
   PubMed Web of Science ®Google Scholar
• Tabakman R, Lecht S, Lazarovici P. Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson’s disease? Bioessays 26(1), 80–90 (2004).
   PubMed Web of Science ®Google Scholar
• Youdim MB, Weinstock M. Molecular basis of neuroprotective activities of rasagiline and the antiAlzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Cell Mol. Neurobiol. 21(6), 555–573 (2001).
   PubMed Web of Science ®Google Scholar
• Carrillo MC, Minami C, Kitani K et al. Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci. 67(5), 577–585 (2000).
   PubMed Web of Science ®Google Scholar
• Maruyama W, Yamamoto T, Kitani K, Carrillo MC, Youdim M, Naoi M. Mechanism underlying anti-apoptotic activity of a (-) deprenyl-related propargylamine, rasagiline. Mech. Ageing Dev. 116(2–3), 181–191 (2000).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N. Engl. J. Med. 328(3), 176–183 (1993).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. N. Engl. J. Med. 321(20), 1364–1371 (1989).
   PubMed Web of Science ®Google Scholar
• Finberg JP, Lamensdorf I, Commissiong JW, Youdim MB. Pharmacology and neuroprotective properties of rasagiline. J. Neural Transm. Suppl. 48, 95–101 (1996).
   PubMedGoogle Scholar
• Youdim MB, Gross A, Finberg JP. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br. J. Pharmacol. 132(2), 500–506 (2001).
   PubMed Web of Science ®Google Scholar
• Lees AJ, Shaw KM, Kohout LJ et al. Deprenyl in Parkinson’s disease. Lancet 2(8042), 791–795 (1977).
   PubMed Web of Science ®Google Scholar
• Myllyla VV, Sotaniemi KA, Vuorinen JA, Heinonen EH. Selegiline in de novo parkinsonian patients: the Finnish study. Mov. Disord. 8(Suppl. 1), S41–S44 (1993).
   Web of Science ®Google Scholar
• Schachter M, Marsden CD, Parkes JD, Jenner P, Testa B. Deprenyl in the management of response fluctuations in patients with Parkinson’s disease on levodopa. J. Neurol. Neurosurg. Psychiatry 43(11), 1016–1021 (1980).
   PubMed Web of Science ®Google Scholar
• Heinonen EH, Rinne UK, Tuominen J. Selegiline in the treatment of daily fluctuations in disability of parkinsonian patients with long-term levodopa treatment. Acta Neurol. Scand. Suppl. 126, 113–118 (1989).
   PubMedGoogle Scholar
• Golbe LI, Lieberman AN, Muenter MD et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson’s disease. Clin. Neuropharmacol. 11(1), 45–55 (1988).
   PubMed Web of Science ®Google Scholar
• Ulm G, Fornadi F. R-(-)-deprenyl in the treatment of end-of-dose akinesia. J. Neural Transm. Suppl. 25, 163–172 (1987).
   PubMedGoogle Scholar
• Hubble JP, Koller WC, Waters C. Effects of selegiline dosing on motor fluctuations in Parkinson’s disease. Clin. Neuropharmacol. 16(1), 83–87 (1993).
   PubMed Web of Science ®Google Scholar
• Mahmood I. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Clin. Pharmacokinet. 33(2), 91–102 (1997).
   PubMed Web of Science ®Google Scholar
• Villemagne V, Yuan J, Wong DF et al. Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations. J. Neurosci. 18(1), 419–427 (1998).
   PubMed Web of Science ®Google Scholar
• Clarke A, Brewer F, Johnson ES et al. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J. Neural Transm. 110(11), 1241–1255 (2003).
   PubMed Web of Science ®Google Scholar
• Clarke A, Johnson ES, Mallard N et al. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition. J. Neural. Transm. 110(11), 1257–1271 (2003).
   PubMed Web of Science ®Google Scholar
• Fahn S, Elton RL. Members of the UPDRS Development Committee, Unified Parkinson’s disease Rating Scale. In: Recent Development in Parkinson’s disease. Fahn SM, Calne DB, Goldstein M (Eds). Macmillan Healthcare Information, Florham Park, NJ, USA (1987).
   Google Scholar
• Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM. Zydis selegiline reduces off time in Parkinson’s disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov. Disord. 19(4), 426–432 (2004).
   PubMed Web of Science ®Google Scholar
• Finberg JP, Wang J, Bankiewicz K, Harvey-White J, Kopin IJ, Goldstein DS. Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey. J. Neural Transm. Suppl. 52, 279–285 (1998).
   PubMedGoogle Scholar
• Lamensdorf I, Youdim MB, Finberg JP. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J. Neurochem. 67(4), 1532–1539 (1996).
   PubMed Web of Science ®Google Scholar
• Huang W, Chen Y, Shohami E, Weinstock M. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur. J. Pharmacol. 366(2–3), 127–135 (1999).
   PubMed Web of Science ®Google Scholar
• Youdim MB, Wadia A, Tatton W, Weinstock M. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann. NY Acad. Sci. 939, 450–458 (2001).
   PubMed Web of Science ®Google Scholar
• Am OB, Amit T, Youdim MB. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci. Lett. 355(3), 169–172 (2004).
   PubMed Web of Science ®Google Scholar
• Yogev-Falach M, Amit T, Bar-Am O, Youdim MB. The importance of propargylamine moiety in the antiParkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing. Faseb. J. 17(15), 2325–2327 (2003).
   PubMed Web of Science ®Google Scholar
• Bar-Am O, Weinreb O, Amit T, Youdim MB. Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. Faseb. J. (2005) (In Press).
   PubMed Web of Science ®Google Scholar
• Thebault JJ, Guillaume M, Levy R. Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy 24(10), 1295–1305 (2004).
   PubMed Web of Science ®Google Scholar
• Rabey JM, Sagi I, Huberman M et al. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson’s disease: a double-blind study as adjunctive therapy to levodopa. Clin. Neuropharmacol. 23(6), 324–330 (2000).
   PubMed Web of Science ®Google Scholar
• Stern MB, Marek KL, Friedman J et al. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson’s disease patients. Mov. Disord. 19(8), 916–923 (2004).
   PubMed Web of Science ®Google Scholar
• Youdim MB, Tipton KF. Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson’s disease. Parkinsonism Relat. Disord. 8(4), 247–253 (2002).
   PubMed Web of Science ®Google Scholar
• Fowler JS, Volkow ND, Logan J et al. Slow recovery of human brain MAO B after L-deprenyl (selegeline) withdrawal. Synapse 18(2), 86–93 (1994).
   PubMed Web of Science ®Google Scholar
• Freedman N, Mishani E, Krausz Y, Blaugrund E, Ehrlich D, Chisin R. In vivo measurement of brain monoamine oxidase B (MAO-B activity after rasagiline treatment, using L-[11C]Deprenyl and positron emission tomography (PET). Movement Disorders S89, 298 (2005).
   Google Scholar
• Speiser Z, Levy R, and Cohen S. Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. J. Neural Transm. Suppl. 52, 287–300 (1998).
   PubMedGoogle Scholar
• Parkinson Study Group. A controlled trial of rasagiline in early Parkinson’s disease: the TEMPO Study. Arch. Neurol. 59(12), 1937–1943 (2002).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson’s disease. Arch. Neurol. 61(4), 561–566 (2004).
   PubMed Web of Science ®Google Scholar
• Leber P. Slowing the progression of Alzheimer’s disease: methodologic issues. Alzheimer Dis. Assoc. Disord. 11(Suppl. 5), S10–S21 (1997).
   PubMed Web of Science ®Google Scholar
• Finberg JP, Takeshima T, Johnston JM, Commissiong JW. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuroreport 9(4), 703–707 (1998).
   PubMed Web of Science ®Google Scholar
• Heikkila RE, Duvoisin RC, Finberg JP, Youdim MB. Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur. J. Pharmacol. 116(3), 313–317 (1985).
   Google Scholar
• Akao Y, Maruyama W, Yi H, Shamoto-Nagai M, Youdim MB, Naoi M. An anti-Parkinson’s disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci. Lett. 326(2), 105–108 (2002).
   PubMed Web of Science ®Google Scholar
• Maruyama W, Nitta A, Shamoto-Nagai M et al. N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor. Neurochem. Int. 44(6), 393–400 (2004).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson’s disease and motor fluctuations: the PRESTO study. Arch. Neurol. 62(2), 241–248 (2005).
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Melamed E et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365(9463), 947–954 (2005).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A controlled trial of lazabemide (Ro 19–6327) in levodopa-treated Parkinson’s disease. Arch. Neurol. 51(4), 342–347 (1994).
   PubMed Web of Science ®Google Scholar
• Turkka J, Suominen K, Tolonen U, Sotaniemi K, Myllyla VV. Selegiline diminishes cardiovascular autonomic responses in Parkinson’s disease. Neurology 48(3), 662–667 (1997).
   PubMed Web of Science ®Google Scholar
• Churchyard A, Mathias CJ, Boonkongchuen P, Lees AJ. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 63(2), 228–234 (1997).
   PubMed Web of Science ®Google Scholar
• Churchyard A, Mathias CJ, Lees AJ. Selegiline-induced postural hypotension in Parkinson’s disease: a longitudinal study on the effects of drug withdrawal. Mov. Disord. 14(2), 246–251 (1999).
   PubMed Web of Science ®Google Scholar
• Abassi ZA, Binah O, Youdim MB. Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline. Br. J. Pharmacol. 143(3), 371–378 (2004).
   PubMed Web of Science ®Google Scholar
• Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson’s disease. Parkinson’s disease Research Group of the United Kingdom. Br. Med. J. 311(7020), 1602–1607 (1995).
   PubMed Web of Science ®Google Scholar
• Ben-Shlomo Y, Churchyard A, Head J et al. Investigation by Parkinson’s disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson’s disease: further results of randomised trial and confidential inquiry. Br. Med. J. 316(7139), 1191–1196 (1998).
   PubMed Web of Science ®Google Scholar
• Olanow CW, Myllyla VV, Sotaniemi KA et al. Effect of selegiline on mortality in patients with Parkinson’s disease: a meta-analysis. Neurology 51(3), 825–830 (1998).
   PubMed Web of Science ®Google Scholar
• Marras C, McDermott MP, Rochon PA et al. Survival in Parkinson’s disease: thirteen-year follow-up of the DATATOP cohort. Neurology 64(1), 87–93 (2005).
   PubMed Web of Science ®Google Scholar
• Fiala KH, Whetteckey J, Manyam BV. Malignant melanoma and levodopa in Parkinson’s disease: causality or coincidence? Parkinsonism Relat. Disord. 9(6), 321–327 (2003).
   PubMed Web of Science ®Google Scholar
• Youdim MB. The advent of selective monoamine oxidase A inhibitor antidepressants devoid of the cheese reaction. Acta Psychiatr. Scand. Suppl. 386, 5–7 (1995).
   PubMedGoogle Scholar
• Sternbach H. The serotonin syndrome. Am. J. Psychiatry 148(6), 705–713 (1991).
   PubMed Web of Science ®Google Scholar
• Lauterbach EC. The neuropsychiatry of Parkinson’s disease and related disorders. Psychiatr. Clin. North Am. 27(4), 801–825 (2004).
   PubMed Web of Science ®Google Scholar
• Suchowersky O, deVries J. Possible interactions between deprenyl and prozac. Can. J. Neurol. Sci. 17(3), 352–353 (1990).
   PubMed Web of Science ®Google Scholar
• Blackwell B. Monoamine oxidase inhibitor interactions with other drugs. J. Clin. Psychopharmacol. 11(1), 55–59 (1991).
   PubMed Web of Science ®Google Scholar
• Ritter JL, Alexander B. Retrospective study of selegiline-antidepressant drug interactions and a review of the literature. Ann. Clin. Psychiatry 9(1), 7–13 (1997).
   PubMedGoogle Scholar
• Waters CH. Fluoxetine and selegiline-lack of significant interaction. Can. J. Neurol. Sci. 21(3), 259–261 (1994).
   PubMed Web of Science ®Google Scholar
• Toyama SC, Iacono RP. Is it safe to combine a selective serotonin re-uptake inhibitor with selegiline? Ann. Pharmacother. 28(3), 405–406 (1994).
   PubMed Web of Science ®Google Scholar